ArticleMedicines (Basel, Switzerland)2020
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience.
Article in Medicines (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors?Journal of neuro-oncology · 2026Pooled it
- Article
- Bioelectromagnetism for Cancer Treatment-Modulated Electro-Hyperthermia.Current oncology (Toronto, Ont.) · 2025Review
- The Complexity of Malignant Glioma Treatment.Cancers · 2025Review
- Review
- Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma.Frontiers in pharmacology · 2023Review
- Engineering Cell Lines for Specific Human Leukocyte Antigen Presentation.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Immunotherapy for the treatment of pediatric brain tumors: a narrative review.Translational pediatrics · 2022Review
- Answer to Commentary on "Systematic review about complementary medical hyperthermia in oncology" by Liebl et al.Clinical and experimental medicine · 2022Article
- Commentary on "Systematic review about complementary medical hyperthermia in oncology" by Liebl et al.Clinical and experimental medicine · 2022Article
- Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy.International journal of molecular sciences · 2022Review
- TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model.International journal of molecular sciences · 2022Article
- Review
- Immunotherapy approaches for the treatment of diffuse midline gliomas.Oncoimmunology · 2022Review
- Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma.EBioMedicine · 2021Review
- Review
- Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit.Biomedicines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.